Amerikanische Gesellschaft für Hirudotherapie

Biochemical characterization of a thrombin inhibitor from the bloodsucking bug Dipetalogaster maximus

Comparative study published in Haemostasis (1999)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Observational studySpeichel-PharmakologieArzneimittelentwicklungLange U et al. · Haemostasis, 1999

Abstract

From the bloodsucking bug Dipetalogaster maximus, a protein with anticoagulant activity was isolated and biochemically characterized. The isolated protein, named dipetalogastin, possesses an average molecular mass of 11.8 kD. Its N-terminal sequence shows homology to rhodniin, a thrombin inhibitor isolated from the bug Rhodnius prolixus. The in vitro anticoagulant activity of dipetalogastin occurs via the inhibition of thrombin. The anticoagulant and thrombin inhibitory potency of dipetalogastin is comparable to that of recombinant hirudin. Its specific thrombin inhibitory activity is 9,300 antithrombin units/mg protein. Dipetalogastin forms only 1:1 molar complexes with thrombin. It is a tight-binding inhibitor of thrombin possessing a dissociation constant of 125 fM. It does not inhibit factor Xa or alpha-chymotrypsin and only weakly inhibits trypsin.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeComparative StudyJournal Article
Indexed MeSH termsAmino Acid SequenceAnimalsAnticoagulantsBlood Coagulation TestsChromatography, AffinityChromatography, GelChromatography, High Pressure LiquidEndopeptidasesEnzyme InhibitorsFactor XFibrinogenHirudins

Zusammenfassung

Dipetalogastin, a thrombin inhibitor from Dipetalogaster maximus, is a tight-binding inhibitor with dissociation constant of 125 fM and specific thrombin inhibitory activity comparable to recombinant hirudin.

Warum dies für die Hirudotherapie relevant ist

This study describes the isolation and biochemical characterization of dipetalogastin, an 11.8 kDa thrombin inhibitor from the bloodsucking bug Dipetalogaster maximus. Dipetalogastin forms a 1:1 complex with thrombin, exhibits a dissociation constant of 125 fM, and has specific thrombin inhibitory activity of 9,300 antithrombin units/mg, which the authors describe as comparable to recombinant hirudin. Its N-terminal sequence shows homology to rhodniin, another insect-derived thrombin inhibitor. The relevance to ASH's domain is indirect: although dipetalogastin is biochemically analogous to leech-derived hirudin as a potent, tight-binding thrombin inhibitor from a blood-feeding invertebrate, it originates from a heteropteran insect, not a leech. No leeches or leech-derived molecules were studied; the hirudin comparison serves solely as a benchmark for inhibitor potency.

Zitation

Biochemical characterization of a thrombin inhibitor from the bloodsucking bug Dipetalogaster maximus.

Lange U et al. · Haemostasis, 1999

DOI

Verwandter klinischer Kontext

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Salivary Gland SecretionAnti-Inflammatory MechanismsSalivary ComplexDrug PipelineDrug DevelopmentDirect Thrombin InhibitorsHirudinAnticoagulation CompoundsHemostasisOtolaryngology

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.